Publications with
engine protein arrays

Protein Arrays can be used for analysis of protein interactions with numerous types of molecules. So they can be applied to determine auto-antibody profiles of complex sera, cross-reactivity of monoclonal antibodies, protein-protein interaction pairs, DNA/RNA binding proteins, etc.

Scientists from all over the world have used the protein arrays successfully.

Our arrays based on the technique of Source Biosciences, imaGenes and RZPD.
You have used our arrays in your paper? Send us your publication!

six proteinarrays for biomarker discovery by fluorescent detection

Almamy A, Schwerk C, Schroten H, Ishikawa H, Asif AR, Reuss B. Crossreactivity of an Antiserum Directed to the Gram-Negative Bacterium Neisseria gonorrhoeae with the SNARE-Complex Protein Snap23 Correlates to Impaired Exocytosis in SH-SY5Y Cells. J Mol Neurosci. 2017;62: 163–180. doi:10.1007/s12031-017-0920-2

Schmitt J, Keller A, Nourkami-Tutdibi N, Heisel S, Habel N, Leidinger P, et al. Autoantibody signature differentiates wilms tumor patients from neuroblastoma patients. PLoS One. 2011;6: 8–14. doi:10.1371/journal.pone.0028951

Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S, et al. Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis. 2014;73: 1211–1214. doi:10.1136/annrheumdis-2012-202208

Hoepfner M, Witte T, Pursche N, Moosig F, Gross W, Schmidt RE, et al. Antibodies binding to DRP-4 and macropain subunit C2 as a potential marker of AOSD. Annu Eur Congr Rheumatol Eur Leag Against Rheum EULAR 2013 Madrid Spain. 2013;72: 1–2. doi:10.1136/annrheumdis-2013-eular.1017

Leidinger P, Keller A, Milchram L, Harz C, Hart M, Werth A, et al. Combination of autoantibody signature with PSA level enables a highly accurate blood-based differentiation of prostate cancer patients from patients with benign prostatic hyperplasia. PLoS One. 2015;10: 1–14. doi:10.1371/journal.pone.0128235

Kijanka G, Hector S, Kay EW, Murray F, Cummins R, Murphy D, et al. Human IgG antibody profiles differentiate between symptomatic patients with and without colorectal cancer. Gut. 2010;59: 69–78. doi:10.1136/gut.2009.178574